Stock Story -
Wellness products company Nature’s Sunshine Products (NASDAQ:NATR) will be announcing earnings results tomorrow after the bell. Here's what to look for.
Nature's Sunshine met analysts' revenue expectations last quarter, reporting revenues of $111 million, up 2.2% year on year. It was a weaker quarter for the company, with a miss of analysts' earnings estimates.
Is Nature's Sunshine a buy or sell going into earnings? Find out by reading the original article on StockStory, it's free.
This quarter, analysts are expecting Nature's Sunshine's revenue to decline 3.6% year on year to $112.3 million, a reversal from the 11.9% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.18 per share.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Nature's Sunshine has missed Wall Street's revenue estimates twice over the last two years.
Looking at Nature's Sunshine's peers in the personal care segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Edgewell Personal Care (NYSE:EPC) posted flat year-on-year revenue, meeting analysts' expectations, and Olaplex (NASDAQ:OLPX) reported a revenue decline of 4.8%, in line with consensus estimates.
Read the full analysis of Edgewell Personal Care's and Olaplex's results on StockStory.
There has been positive sentiment among investors in the personal care segment, with share prices up 3.4% on average over the last month. Nature's Sunshine is up 1.3% during the same time and is heading into earnings with an average analyst price target of $23 (compared to the current share price of $14.45).